Top-Rated StocksTop-RatedNASDAQ:IDYA IDEAYA Biosciences (IDYA) Stock Forecast, Price & News $27.71 -0.48 (-1.70%) (As of 02:10 PM ET) Add Compare Share Share Today's Range$27.68▼$28.2950-Day Range$21.07▼$29.7752-Week Range$11.04▼$30.25Volume126,298 shsAverage Volume539,049 shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/APrice Target$32.08 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability IDEAYA Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15.8% Upside$32.08 Price TargetShort InterestBearish13.28% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.88Based on 6 Articles This WeekInsider TradingSelling Shares$827,735 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.01) to ($2.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector510th out of 968 stocksPharmaceutical Preparations Industry221st out of 445 stocks 3.5 Analyst's Opinion Consensus RatingIDEAYA Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.08, IDEAYA Biosciences has a forecasted upside of 15.8% from its current price of $27.71.Amount of Analyst CoverageIDEAYA Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.28% of the float of IDEAYA Biosciences has been sold short.Short Interest Ratio / Days to CoverIDEAYA Biosciences has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in IDEAYA Biosciences has recently increased by 4.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIDEAYA Biosciences does not currently pay a dividend.Dividend GrowthIDEAYA Biosciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEAYA Biosciences has received a 77.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEAYA Biosciences is -0.62. Previous Next 3.8 News and Social Media Coverage News SentimentIDEAYA Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for IDEAYA Biosciences this week, compared to 3 articles on an average week.Search Interest4 people have searched for IDYA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows4 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $827,735.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of IDEAYA Biosciences is held by insiders.Percentage Held by Institutions98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($2.01) to ($2.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEAYA Biosciences is -19.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEAYA Biosciences is -19.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIDEAYA Biosciences has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IDEAYA Biosciences (NASDAQ:IDYA) StockIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More IDYA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDYA Stock News HeadlinesSeptember 16, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for IDEAYA Biosciences, Inc.'s Q1 2024 Earnings (NASDAQ:IDYA)September 15, 2023 | finance.yahoo.comInsider Sell: Chief Legal Officer Jason Throne Sells 1,000 Shares of IDEAYA Biosciences IncSeptember 22, 2023 | UNKNOWN (Ad)Bringing Space Down to EarthCutting edge, AI-powered, Space-based Earth-observation solutionsSeptember 15, 2023 | americanbankingnews.comWedbush Comments on IDEAYA Biosciences, Inc.'s FY2027 Earnings (NASDAQ:IDYA)September 15, 2023 | americanbankingnews.comLeerink Partnrs Analysts Raise Earnings Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA)September 13, 2023 | americanbankingnews.comIDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $37.00September 13, 2023 | msn.comGoldman Sachs Maintains Ideaya Biosciences (IDYA) Buy RecommendationSeptember 13, 2023 | msn.comWedbush Maintains Ideaya Biosciences (IDYA) Outperform RecommendationSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 13, 2023 | americanbankingnews.comWedbush Increases IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $43.00September 12, 2023 | markets.businessinsider.com7 Analysts Have This to Say About IDEAYA BiosciencesSeptember 11, 2023 | finance.yahoo.comIDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid TumorsSeptember 5, 2023 | prnewswire.comIDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations EventsAugust 31, 2023 | msn.comIdeaya Biosciences (IDYA) Price Target Increased by 6.31% to 35.78August 20, 2023 | finance.yahoo.comBroker Revenue Forecasts For IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Are Surging HigherAugust 18, 2023 | nasdaq.comJP Morgan Maintains Ideaya Biosciences (IDYA) Overweight RecommendationAugust 14, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)August 12, 2023 | msn.comRBC Capital Maintains Ideaya Biosciences (IDYA) Outperform RecommendationAugust 12, 2023 | msn.comOppenheimer Maintains Ideaya Biosciences (IDYA) Outperform RecommendationAugust 11, 2023 | msn.comIdeaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside AheadAugust 11, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for IDEAYA BiosciencesAugust 10, 2023 | msn.comIDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue EstimatesAugust 10, 2023 | finance.yahoo.comIDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 9, 2023 | msn.comSVB Leerink Initiates Coverage of Ideaya Biosciences (IDYA) with Outperform RecommendationAugust 2, 2023 | finance.yahoo.comIDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) TumorsAugust 1, 2023 | finance.yahoo.comIDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations EventJune 22, 2023 | finance.yahoo.comIDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib MonotherapySee More Headlines Receive IDYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address IDYA Company Calendar Last Earnings8/10/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IDYA CUSIPN/A CIK1676725 Webwww.ideayabio.com Phone(650) 443-6209FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.08 High Stock Price Forecast$43.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+13.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,650,000.00 Net Margins-164.25% Pretax Margin-164.25% Return on Equity-19.09% Return on Assets-17.54% Debt Debt-to-Equity RatioN/A Current Ratio19.81 Quick Ratio19.80 Sales & Book Value Annual Sales$50.93 million Price / Sales31.86 Cash FlowN/A Price / Cash FlowN/A Book Value$7.26 per share Price / Book3.88Miscellaneous Outstanding Shares57,560,000Free Float54,623,000Market Cap$1.62 billion OptionableNot Optionable Beta0.75 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Yujiro S. Hata (Age 49)Co-Founder, Pres, CEO & Director Comp: $851.7kDr. Michael A. White Ph.D. (Age 57)Chief Scientific Officer Comp: $613.85kDr. Darrin M. Beaupre M.D. (Age 56)Ph.D., Chief Medical Officer Comp: $152.64kDr. Jeffrey Hager Ph.D. (Age 58)Co -Founder Mr. Paul A. Stone J.D. (Age 59)Chief Financial Officer Mr. Andres Ruiz Briseno CPA (Age 37)Principal Accounting Officer, Sr. VP and Head of Fin. & Investor Relations Dr. Paul A. Barsanti Ph.D.Chief Technology OfficerMr. Jason S. Throne Esq. (Age 51)J.D., Chief Legal Officer & Company Sec. Dr. Matthew Maurer M.D.VP and Head of Medical Affairs & Clinical OncologyMr. Mick O'QuigleySr. VP of Devel. OperationsMore ExecutivesKey CompetitorsCureVacNASDAQ:CVACCrinetics PharmaceuticalsNASDAQ:CRNXZentalis PharmaceuticalsNASDAQ:ZNTLSupernus PharmaceuticalsNASDAQ:SUPNPacira BioSciencesNASDAQ:PCRXView All CompetitorsInsiders & InstitutionsHalpern Financial Inc.Bought 2,250 shares on 9/21/2023Ownership: 0.004%Jason ThroneSold 1,000 sharesTotal: $30,000.00 ($30.00/share)Tucker Asset Management LLCBought 2,607 shares on 9/8/2023Ownership: 0.005%Jason ThroneSold 1,737 sharesTotal: $52,162.11 ($30.03/share)Jason ThroneSold 2,100 sharesTotal: $63,063.00 ($30.03/share)View All Insider TransactionsView All Institutional Transactions IDYA Stock - Frequently Asked Questions Should I buy or sell IDEAYA Biosciences stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDYA shares. View IDYA analyst ratings or view top-rated stocks. What is IDEAYA Biosciences' stock price forecast for 2023? 14 equities research analysts have issued 1 year price targets for IDEAYA Biosciences' shares. Their IDYA share price forecasts range from $24.00 to $43.00. On average, they predict the company's share price to reach $32.08 in the next year. This suggests a possible upside of 13.8% from the stock's current price. View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts. How have IDYA shares performed in 2023? IDEAYA Biosciences' stock was trading at $18.17 at the beginning of the year. Since then, IDYA shares have increased by 55.1% and is now trading at $28.19. View the best growth stocks for 2023 here. When is IDEAYA Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our IDYA earnings forecast. How were IDEAYA Biosciences' earnings last quarter? IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The company earned $3.50 million during the quarter, compared to the consensus estimate of $4.89 million. IDEAYA Biosciences had a negative net margin of 164.25% and a negative trailing twelve-month return on equity of 19.09%. The business's revenue for the quarter was down 55.7% on a year-over-year basis. What ETFs hold IDEAYA Biosciences' stock? ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of IDEAYA Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA). When did IDEAYA Biosciences IPO? (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO. What is IDEAYA Biosciences' stock symbol? IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA." Who are IDEAYA Biosciences' major shareholders? IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.87%), BlackRock Inc. (7.60%), State Street Corp (3.72%), Dimensional Fund Advisors LP (1.90%), Geode Capital Management LLC (1.79%) and Platinum Investment Management Ltd. (1.42%). Insiders that own company stock include Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone and Ventures Iv LP 5Am. View institutional ownership trends. How do I buy shares of IDEAYA Biosciences? Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IDEAYA Biosciences' stock price today? One share of IDYA stock can currently be purchased for approximately $28.19. How much money does IDEAYA Biosciences make? IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $1.62 billion and generates $50.93 million in revenue each year. The company earns $-58,650,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. How many employees does IDEAYA Biosciences have? The company employs 116 workers across the globe. How can I contact IDEAYA Biosciences? IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com. This page (NASDAQ:IDYA) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.